Heart patients get new hope: varenicline vs. nicotine patch in quitting smoking
NCT ID NCT00959972
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether varenicline (Chantix) helps smokers with coronary heart disease quit better than the standard nicotine patch. Fifty motivated smokers who had a heart-related event were randomly assigned to one of the two treatments for 12 weeks. The main goal was to see who stayed smoke-free, confirmed by breath tests, during the final weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Varenicline (Chantix) and transdermal nicotine patch
What this could lead to
If varenicline works better than the patch, it could give heart patients a more effective way to quit smoking and reduce their risk of future heart problems.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. The trial is already completed, and the findings may not lead to a change in standard care without larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada